RT Journal Article
SR Electronic
T1 Prognostic Factors for Pancreatic Cancer Patients Treated with Immune-cell Therapy
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 4353
OP 4360
DO 10.21873/anticanres.12736
VO 38
IS 7
A1 KAORI MAKITA
A1 TAKASHI KAMIGAKI
A1 SACHIKO OKADA
A1 ERIKO MATSUDA
A1 HIROSHI IBE
A1 ERI OGUMA
A1 KEIKO NAITOH
A1 RISHU TAKIMOTO
A1 SHIGENORI GOTO
YR 2018
UL http://ar.iiarjournals.org/content/38/7/4353.abstract
AB Background/Aim: The past 17 years, immune-cell therapy has been administered to 990 patients with advanced or recurrent pancreatic adenocarcinoma and 50 patients with curatively resected pancreatic adenocarcinoma. Materials and Methods: The correlation between overall survival (OS) and various factors including sex, age, performance status (PS), distant metastasis, chemotherapy, radiotherapy, and type of immune-cell therapy were evaluated by univariate and multivariate analyses. Results: The median OS of advanced or recurrent pancreatic cancer was 5.8 months, and the prognosis was improved in pancreatic cancer patients who received immune-cell therapy with PS scores of 0-1 [hazard risk (HR)=0.56; 95% confidence interval (CI)=0.46-0.68; p<0.0001], chemotherapy (HR=0.68; 95%CI=0.54-0.87; p=0.002), or radiotherapy (HR=0.76; 95%CI=0.63-0.93; p=0.006). Multivariate analysis demonstrated that distant metastasis indicated a poor prognosis for pancreatic cancer patients that were administered immune-cell therapy (HR=1.62; 95%CI=1.37-1.93; p<0.0001). Additionally, the combined immune-cell therapy with αβ T cell and dendritic cell (DC) vaccine provided a survival benefit in advanced or recurrent pancreatic cancer patients (HR=0.69; 95%CI=0.57-0.83; p<0.0001). Conclusion: A survival benefit could be potentially obtained with better PS by the combination of αβ T cell therapy, DC vaccine therapy, and chemotherapy at an early stage in pancreatic cancer.